

Study Type	Age	Study Name/URL	Location	Contact	Intervention	URL
Drug	18 Years to 65 Years	A Study of LY900014 and Insulin Degludec in Participants With Type 1 Diabetes	HealthPartners Institute/ IDC SLP	1-877-285-4559 Lily	Drug: LY900014 Drug: Insulin Degludec	https://clinicaltrials.gov/ct2/show/NCT04585776
Drug/Device/NewlyDiagnosed	7 Years to 17 Years	Hybrid Closed Loop Therapy and Verapamil for Beta Cell Preservation in New Onset Type 1 Diabetes	U of Minnesota-MPLS CLVer Study	Shannon Beasley Beas1103@umn.edu 612-626-5609	Device: HCL Drug: verapamil 120mg tablet Device: non-HCL Drug: placebo	https://ClinicalTrials.gov/show/NCT04233034
Drug/ Newly Diagnosed	18 Yearsto 45 Years	TN27: A Multiple Ascending Dose Trial Investigating Safety, Tolerability and Pharmacokinetics of NNC0361-0041 TOPPLE	U of Minnesota-MPLS	Beth Pappenfus 612-624-2922	Drug: NNC0361-0041 Drug: Placebo	https://ClinicalTrials.gov/show/NCT04279613
Drug	18 Years to 75 Years	Effects of Ondansetron on Gastrointestinal Sensorimotor Dysfunctions in Diabetes Mellitus and Dyspepsia	Mayo Clinic	Kelly Faverhak 507-255-6802 feverhak.kelly@mayo.edu	Drug: Ondansetron 8mg Drug: Placebo	https://ClinicalTrials.gov/show/NCT03865290
Drug	18 Years to 75 Years	Safety,Tolerability and Efficacy of LMB763 in Diabetic Nephropathy		Novartis 1-888-669-6682 Novartis.email@novartis.com	Drug: LMB763 Other: Placebo	https://ClinicalTrials.gov/show/NCT03804879
Drug	3 Years to Older Adult	Hydroxychloroquine in Individuals At-risk for Type 1 Diabetes Mellitus	U of Minnesota MPLS	Darcy Weingarter 612-624-5958 darcy@umn.edu Jessica Ruedy 612-624-6617 Sweet093.umn.edu	Drug: Hydroxychloro-quine Drug: Placebo	https://ClinicalTrials.gov/show/NCT03428945
Drug	18 Years to 65 Years	Naloxone, Hypoglycemia and Exercise	U of Minnesota-MPLS	Anjali Kumar 612-301-7040 studydiabetes@umn.edu	Drug: Naloxone Drug: Placebo	https://ClinicalTrials.gov/show/NCT03149770
Drug	18 Years to Older Adult	Insulin Degludec for the Management of Patient With Recurrent Diabetic Ketoacidosis	HCMC- Hennepin Country Med Center	Lisa Fish 612-873-8760 Lisa.Fish2hcmc.org	Drug: Degludec Drug: Standard long-acting	https://ClinicalTrials.gov/show/NCT03001323
Drug/ insulin	65 Year sand older	Automated Insulin Delivery in Elderly With Type 1 Diabetes (AIDE T1D)	Mayo Clinic	Shelly McCrady-Spitzer McCrady.Shelly@mayo.edu	Device: Tandom t:slim X2 with HCL or PLGS	https://ClinicalTrials.gov/show/NCT04016662
Drug/ Insulin	18 Years to 70 Years	Comparison of Glucose Values and Variability Between TOUJEO and TRESIBA During Continuous Glucose Monitoring in T 1D	Health Partners Inst-IDC -SLP	Caitlin Hasledalen IDCResearch@parknicollet.com	Drug: Insulin glargine, 300 U/ml Drug: Insulin degludec, 100U/ml Drug: Background	https://ClinicalTrials.gov/show/NCT04075513
Device	18 Years to older adult	The International Diabetes Closed Loop (IDCL) Trial: Protocol 4	Mayo Clinic	Shelly McCrady-Spitzer McCrady.Shelly@mayo.edu 507-255-5916	Device: interoperable Artificial Pancreas System (iAPS) Other: Sensor-Augmented Pump (SAP)/Predictive Low Glucose Suspend (PLGS)	https://ClinicalTrials.gov/show/NCT04436796
Device	2 Years to 80 Years	Feasibility Studies of Personalized Closed Loop	Mayo Clinic	Shelly McCrady-Spitzer McCrady.Shelly@mayo.edu 507-255-5916	Device: Cloud-based Digital Twin and Meal Prediction algorithms	https://ClinicalTrials.gov/show/NCT04203823
Device	2 Years to 80 Years	Multi-center Trial in Adult and Pediatric Patients With Type 1 Diabetes Using Hybrid Closed Loop System and Control at Home	Mayo Clinic And Sanford Health	Mayo-Shelly McCrady-Spitzer, mccrady.shelly@mayo.edu Sanford- Misty Small 605-328-1390	Device: 670G Insulin Pump Device: Subject's Current Diabetes Therapy	https://ClinicalTrials.gov/show/NCT02748018
Pregnancy/Device	18 Years to 45 Years	Supervised Safety and Feasibility Evaluation of Automated Insulin Delivery in Pregnant Patients With Type 1 Diabetes	Mayo Clinic	Shelly McCrady-Spitzer, mccrady.shelly@mayo.edu 507-255-5916	Device: Automated Insulin Delivery	https://ClinicalTrials.gov/show/NCT04492566
Pregnancy/Device	18 Years to 40 Years	Longitudinal Observation of Insulin Requirements and Sensor Use in Pregnancy	Mayo Clinic	Shelly McCrady-Spitzer, mccrady.shelly@mayo.edu 507-255-5916	Device: Dexcom G6 CGM	https://ClinicalTrials.gov/show/NCT03761615
Prevention	Ages 0-5 Years	General Population Level Estimation for Type 1 Diabetes Risk in Children 0-5 Years Old During Routine Care Delivery	Sanford Health Sioux Falls, SD	Ann Mays Ann.mays@sanfordhealth.org 605-312-6052	Diagnostic Test: Sera and whole blood sampling Diagnostic Test: Differential Gene Expression (DGE)	https://ClinicalTrials.gov/show/NCT04477928
Prevention	30 mos to 45 Years	TrialNet Pathway to Prevention of T1D	U of Minnesota-MPLS	Beth Pappenfus 612-624-2922	For those who have relatives with T1D.	https://ClinicalTrials.gov/show/NCT00097292
Other: Experimental	18 Years to 65 Years	Recurrent Hypoglycemia in Type 1 Diabetes (Aim 2)	U of Minnesota-MPLS	studydiabetes@umn.edu 612-624-9176		https://ClinicalTrials.gov/show/NCT04387422
Other: Experimental	18 Years to 65 Years	Recurrent Hypoglycemia in Type 1 Diabetes (Aim 1)	U of Minnesota-MPLS	studydiabetes@umn.edu 612-624-9176		https://ClinicalTrials.gov/show/NCT03410277
Other: Hypo-Glycemia	18 Years to 65 Years	Measurement of Glucose Metabolism in Humans: Effect of Recurrent Hypoglycemia on Hypothalamic GABA	U of Minnesota-MPLS	Anjali Kumar PAC 612-301-7040		https://ClinicalTrials.gov/show/NCT02829593 studydiabetes@umn.edu

Encapsulation device	18 Years to 65 Years	A Safety, Tolerability, and Efficacy Study of VC-02 Combination Product in Subjects With Type 1 Diabetes Mellitus and Hypoglycemia Unawareness	U of Minnesota-MPLS	612-626-4993 kree001@umn.edu	EncapsulationDevice	https://ClinicalTrials.gov/show/NCT03163511
Other:Vaccine	3 Years to 18 Years	A Study to Evaluate Pneumococcal Polysaccharide Vaccine Effectiveness in Children With Type 1 Diabetes	Mayo Clinic	Shelly McCrady-Spitzer mccrady.shelly@mayo.edu		https://ClinicalTrials.gov/show/NCT04481243
Other: Cell Therapy	Ages 45 to 75 Years	Patient-Derived Stem Cell Therapy for Diabetic Kidney Disease	Mayo Clinic	Shelly McCrady-Spitzer mccrady.shelly@mayo.edu	Phase 1	https://ClinicalTrials.gov/show/NCT0380343
Prevention	Ages 0-5 Years	Prevention General Population Level Estimation for Type 1 Diabetes Risk in Children 0-5 Years Old During Routine Care Delivery	Sanford Health Sioux Falls, SD	Ann.mays@sanfordhealth.org 605-312-6052	Diagnostic Test: Sera and whole blood sampling Diagnostic Test: Differential Gene Expression (DGE)	https://ClinicalTrials.gov/show/NCT04477928
Device	2 Years to 80 Years	Multi-center Trial in Adult and Pediatric Patients With Type 1 Diabetes Using Hybrid Closed Loop System and Control at Home	Sanford Health	Sanford- Misty Small 605-328-1390	Device: 670G Insulin Pump Device: Subject's Current Diabetes Therapy	https://ClinicalTrials.gov/show/NCT02748018
Prevention	30 mos to 45 Years	TrialNet Pathway to Prevention of T1D For those who have relatives with T1D.	Sanford Health	Sioux Falls, SD 605-328-1368 Fargo, ND 701-234-2382	For those who have relatives with T1D.	https://ClinicalTrials.gov/show/NCT00097292
DRUG Newly Diagnosed	Ages 8 Years to 17 Years	PROTECT Study - Newly Diagnosed within 6 weeks.	Sanford Health	Hanna Williams MD,PHD 605-328-1368	Drug: Teplizumab	https://ClinicalTrials.gov/show/NCT03875729

For more information on clinical studies please contact Debbie Evans debbieaeavans1@gmail.com or leave a message at 612-810-1933.